All Blogs
Sep 18, 2026
Scholar Rock’s ISEMBYLD Sets a New Course in SMA With Muscle-Targeted Therapy
Summary The FDA approved Scholar Rock’s ISEMBYLD on September 11, 2026, the first and only muscle-targeted therapy for SMA, for adults and children aged 2+ who are already on an SMN2-targeted treatment. The FDA approval was based on the Phase 3 SAPPHIRE trial, which enrolled 188 patients aged 2–21 with 5q S...
Read More...
Sep 17, 2026
Ferronova Announces Preliminary MAGMAP Results in 62-Patient Gastric and Oesophageal Cancer Trial; Powerful Medical Secures FDA De Novo Authorization for AI ECG Model; ZEISS Advances Cataract Surgery with Introduction of AT LUCIA toric 721P; Waters Launches BD FACSDiscover A7 Cell Analyzer for Standardized Spectral Flow Cytometry; Nicklaus Children’s Hospital Completes One of the Country’s First Transcatheter Fontan Procedures in a Two-Year-Old
Ferronova Announced Preliminary Results of MAGMAP, a 62-Patient Gastric and Oesophageal Cancer Trial Investigating Lymph Node Mapping On 09 September 2026, Emboline announced that it had received U.S. FDA 510(k) clearance for its Emboliner Embolic Protection System, supporting the company's advancement in the em...
Read More...
Sep 16, 2026
Software as a Medical Device: The Invisible Engine of Digital Health
Healthcare used to be defined by devices you could hold: a stethoscope, an MRI scanner, an insulin pump. Increasingly, it's defined by devices you can't hold at all. An algorithm that flags a suspicious mole from a smartphone photo. A program that reads a chest CT and prioritizes the most urgent case in a radiologi...
Read More...
Sep 15, 2026
TAGRISSO Delivers Landmark Eight-Year Survival Outcomes in Early-Stage EGFR-Mutated Lung Cancer; Scholar Rock Receives FDA Approval for ISEMBYLD; Pharming’s Joenja Receives FDA Approval as First U.S. Treatment for Children With APDS; AbbVie Reports Positive Phase 3 Results for Atogepant in Menstrual Migraine; Rezera’s Ruvonoflast Delivers Positive Inflammation Results with Favorable Safety in RESOLVE-1
TAGRISSO Demonstrates Eight-Year Landmark Survival Benefit for Patients with Early-Stage EGFR-Mutated Lung Cancer Updated exploratory findings from the Phase III ADAURA trial demonstrated that AstraZeneca’s Tagrisso (osimertinib) continued to provide a sustained and clinically meaningful overall survival (OS) be...
Read More...
Sep 14, 2026
Novartis’ Pipeline Setback in 2026: Two Trial Failures, One Brutal Week
Summary Novartis faced an unusually difficult period in late August–September 2026, with two Phase 3 programs (pelacarsen and del-desiran) failing their primary endpoints and eight rap-cel autoimmune trials paused following three patient deaths. The back-to-back setbacks triggered a sharp market response, wi...
Read More...
Sep 11, 2026
ADBRY vs DUPIXENT: The Battle for Atopic Dermatitis Supremacy
Summary For decades, moderate-to-severe atopic dermatitis (AD) was managed with topical steroids, calcineurin inhibitors, and broad immunosuppressants, until targeted biologics transformed care. Two biologics dominate: DUPIXENT (dupilumab) by Sanofi/Regeneron and ADBRY (tralokinumab) by LEO Pharma; both targ...
Read More...
Sep 10, 2026
Emboline Secures FDA 510(k) Clearance for Emboliner® Embolic Protection System; Alcon’s Clareon Monofocal IOL Secures EU MDR Certification from TÜV SÜD; Shoulder Innovations Enters Exclusive Partnership with ALM Ortho for Complex Shoulder Reconstruction Solutions; Avo Expands MEDITECH Alliance, Bringing Full Suite of AI Solutions to EHR; Nicklaus Children’s Hospital Performs Pioneering Transcatheter Fontan Completion in Two-Year-Old Child; AEYE Health Publishes AEYE-DS Clinical Trial Results Demonstrating High Diagnostic Accuracy and >99% Imageability
Emboline Received U.S. FDA 510(k) Clearance for Emboliner® Embolic Protection System On 09 September 2026, Emboline announced that it had received U.S. FDA 510(k) clearance for its Emboliner Embolic Protection System, supporting the company's advancement in the embolic protection device market. The system ...
Read More...
Sep 09, 2026
Digital Diabetes Management: How Data, Devices, and AI Are Rewriting the Rules of Glucose Care
Diabetes care used to run on snapshots: a fasting glucose check here, a quarterly HbA1c test there. Between those snapshots, patients were essentially flying blind, making daily decisions about food, insulin, and activity without knowing how their body was actually responding. That gap is closing fast. Digital diab...
Read More...
Sep 08, 2026
Novo Nordisk’s STEP Young Phase 3 Results Highlight Semaglutide’s Potential in Pediatric Obesity; Clover Reports Positive Phase 2 Clinical Findings for RSV + hMPV ± PIV3 Vaccine Candidates; Novartis Reveals Topline Results From Phase III Lp(a)HORIZON Trial of Pelacarsen; US Approves Etcamah Plus CDK4/6 Inhibitor for 1st-Line Advanced HR-Positive Breast Cancer; ZANVASTRO Wins FDA Approval as a First-of-Its-Kind Disease-Modifying Treatment for Alexander Disease
Novo Nordisk’s STEP Young Phase 3 Study Shows Semaglutide Reduced Obesity Classification in 40.4% of Children Novo Nordisk announced the initial results from the STEP Young Phase 3 trial, which evaluated once-weekly semaglutide in combination with lifestyle modifications, including a reduced-calorie diet and inc...
Read More...
Sep 07, 2026
Rare Disease Drug Approvals: Why Are Ultra-Orphan Therapies Suddenly Big Pharma’s Favorite Gamble?
Summary Diseases once dismissed as “too rare to matter” (hundreds to low‑thousands of patients globally) are now central to innovation, with regulators, payers, and major companies adapting fast. In the first eight months of 2026, the FDA cleared more than 6 first‑in‑class drugs, a pace that historically too...
Read More...